- Pazufloxacin
- Pazufloxacin mesilate
- Pazufloxacin mesilate
- 127-06-0Acetone oxime
- 127060-75-7CGP 42112
- 127-07-1Urea,N-hydroxy-
- 127075-47-2(S)-2-Pyrrolidinemethanesulfonic acid
- 12707-58-3Ganglioside GD1a
- 127-08-2Potassium Acetate
- 127087-87-0Poly(oxy-1,2-ethanediyl),a-(4-nonylphenyl)-w-hydroxy-, branched
- 127-09-3Sodium acetate
- 127095-92-5Cyclohexanepropanoicacid, a-[[(1,1-dimethylethoxy)carbonyl]amino]-,(aR)-
- 127095-97-0L-Tyrosine,N-[(1,1-dimethylethoxy)carbonyl]-3-methoxy-O-methyl-
Hot Products
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
- 7631-86-9Silicon dioxide
- 302-79-4Tretinoin
- 77-92-9Citric acid
|
Basic Information |
|
Post buying leads |
|
Suppliers |
|
Cas Database |
| Name |
Pazufloxacin |
EINECS | 635-036-1 |
| CAS No. | 127045-41-4 | Density | 1.56 g/cm3 |
| PSA | 94.55000 | LogP | 2.44030 |
| Solubility | N/A | Melting Point |
269-271 °C |
| Formula | C16H15FN2O4 | Boiling Point | 531.5 °C at 760 mmHg |
| Molecular Weight | 318.305 | Flash Point | 275.2 °C |
| Transport Information | N/A | Appearance | like white to light yellow crystalline |
| Safety | 36/37 | Risk Codes | 20/21/22 |
| Molecular Structure |
|
Hazard Symbols |
 Xn, C, F
|
| Synonyms |
Pasil;Pasil (TN);PZFX;7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-, (S)-;7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6- carboxylic acid,10-(1-aminocyclopropyl)-9- fluoro-2,3-dihydro-3-methyl-7-oxo-,(3S)-;T 3761;(-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid;7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-;T-3761;Pazufloxacin Mesylas;Pazufloxaxin;(S)-10-(1-aminocyclopropyl)-9-fluoro-3-methy...; |
Article Data | 2 |
Pazufloxacin Chemical Properties
Systematic Name: (3S)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
Synonyms of Pazufloxacin (CAS NO.127045-41-4): (-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid ; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)- ; H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-, (S)-
Product Categories: BacteriostaticAntibiotics;ChinolonesAlphabetic;PA - PENAnalytical Standards;Pharmacology Standards;Antibiotics;Chemical Structure;Chromatography;P;Principle;API's
CAS NO:127045-41-4
Molecular Formula: C16H15FN2O4
Molecular Weight: 318.3
Molecular Structure:
Index of Refraction: 1.692
Surface Tension: 76.4 dyne/cm
Density: 1.56 g/cm3
Flash Point: 275.2 °C
Enthalpy of Vaporization: 84.94 kJ/mol
Boiling Point: 531.5 °C at 760 mmHg
Vapour Pressure: 4E-12 mmHg at 25°C
Melting Point: 269-271°C
Pazufloxacin Uses
Pazufloxacin (CAS NO.127045-41-4) is used for the treatment of acute and chronic pneumonia, respiratory infections and other illnesses.
Pazufloxacin Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD | oral | > 2gm/kg (2000mg/kg) | Japanese Journal of Antibiotics. Vol. 48, Pg. 754, 1995. | |
| dog | LDLo | intravenous | 400mg/kg (400mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD GASTROINTESTINAL: NAUSEA OR VOMITING | Japanese Journal of Antibiotics. Vol. 48, Pg. 754, 1995. |
| mouse | LD | oral | > 5gm/kg (5000mg/kg) | Japanese Journal of Antibiotics. Vol. 48, Pg. 754, 1995. | |
| mouse | LD | subcutaneous | > 5gm/kg (5000mg/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | Japanese Journal of Antibiotics. Vol. 48, Pg. 754, 1995. |
| mouse | LD50 | intravenous | 783mg/kg (783mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Japanese Journal of Antibiotics. Vol. 48, Pg. 754, 1995. |
| rat | LD | oral | > 5gm/kg (5000mg/kg) | Chemotherapy Vol. 43(Suppl, | |
| rat | LD | subcutaneous | > 5gm/kg (5000mg/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | Japanese Journal of Antibiotics. Vol. 48, Pg. 754, 1995. |
| rat | LD50 | intravenous | 341mg/kg (341mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Japanese Journal of Antibiotics. Vol. 48, Pg. 754, 1995. |
Pazufloxacin Safety Profile
Hazard Codes: 
Xn,
C,
F
Risk Statements: 20/21/22-34-11
R11: Pazufloxacin (CAS NO.127045-41-4) is highly flammable.
R34: Causes burns.
R20/21/22: Harmful by inhalation, in contact with skin and if swallowed.
Safety Statements: 45-36/37/39-26-16
S16: Keep Pazufloxacin (CAS NO.127045-41-4) away from sources of ignition.
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S36/37/39: Wear suitable protective clothing, gloves and eye/face protection.
RTECS: UU8815300
What can I do for you?
Get Best Price
